DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection

Information source: Spectrum Health Hospitals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Clostridium Difficile Infection

Intervention: Vancomycin (Drug); fruit juice/placebo (Dietary Supplement)

Phase: Phase 4

Status: Recruiting

Sponsored by: Spectrum Health Hospitals

Official(s) and/or principal investigator(s):
Andrew Maternowski, MD, Principal Investigator, Affiliation: Spectrum Health Hospitals

Summary

We are doing this research study to determine if taking vancomycin in addition to a broad-spectrum antibiotic will decrease the chance of developing recurrent Clostridium difficile infection.

Clinical Details

Official title: Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Primary outcome: The incidence of recurrent Clostridium difficile infection

Detailed description: To determine whether prophylactic use of oral vancomycin reduces the incidence of recurrent Clostridium difficile infection (RCDI) in hospitalized patients admitted from their home or another health care facility (HCF) who are exposed to concurrent broad spectrum antibiotics. This is a randomized research study, which means that the treatment you get will be chosen by chance, like flipping a coin. You will have a 50/50 chance of receiving one of the following: 1. Group 1 (Treatment Group): single daily dose of vancomycin in liquid form (study medication). 2. Group 2 (Placebo Group): single daily dose of placebo (a placebo will look just like the study medication, but contains no medication, only a substance like sterile water). Depending on the group you are placed in (which is chosen by a computer), you will receive either a daily dose of the study medication or a daily dose of the placebo for a total of ten days. If you are discharged from the hospital prior to ten days, you will be given the study medication to complete outside of the hospital with written instructions. A member of the Research staff will monitor you daily during the 10 days of treatment for any adverse reactions or any signs and symptoms of recurrent Clostridium difficile infection. If you are discharged prior to ten days, the monitoring will take place via telephone call daily until completion of the ten day treatment. You will be contacted again by telephone at 1, 3, and 6 months after completion of the study medication to inquire about your general health and any changes in health status. Other medical information from your records and charts may also be collected by us for purposes of review for this study.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. In patients >19 years of age 2. History of C. difficile diarrhea within 16 weeks and treated with Flagyl or Vancomycin during last episode. 3. Patients started on antibiotics during current admission for any other indication at any point of time during hospital course. Exclusion Criteria: 1. Current diagnosis of CDI 2. First episode of CDI during this admission. 3. Allergy to Vancomycin or other known intolerance 4. Pregnant h) Patient has received broad-spectrum antibiotics for more than 48 hours for this admission j) Incarceration

Locations and Contacts

Spectrum Health Hospital, Grand Rapids, Michigan 49503, United States; Recruiting
Mary E Readwin, RN, Phone: 616-486-2043, Email: mary.readwin@spectrumhealth.org
Andrew P Maternowski, MD, Principal Investigator
Additional Information

Starting date: August 2014
Last updated: September 10, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017